Georgia's Online Cancer Information Center

Unknown Primary Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Unknown Primary
Cancer Type = Unknown Primary
There are currently 113 active Unknown Primary clinical trials in Georgia.
5.
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Cancer Type
Unknown Primary
NCT ID
NCT02817633
Protocol IDs
4020-01-001
NCI-2016-01254
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03849469
Protocol IDs
XmAb22841-01
NCI-2019-02498
DUET-4
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Cancer Type
Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03424603
Protocol IDs
STRO-001-BCM1
NCI-2018-00484
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
10.
A Phase 1 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (ARTISTRY-2)
Cancer Type
Unknown Primary
NCT ID
NCT03861793
Protocol IDs
ALKS 4230-001
NCI-2019-02348
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
A Phase 1 Study of ASP1951 in Subjects With Advanced Solid Tumors
Cancer Type
Lung Cancer, Prostate Cancer , Unknown Primary
NCT ID
NCT03799003
Protocol IDs
1951-CL-0101
NCI-2019-02414
Treatment Sites (1)
12.
A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors
Cancer Type
Unknown Primary
NCT ID
NCT03030378
Protocol IDs
10061
10061
NCI-2017-00091
HCC 17-003
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
13.
A Phase 1 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors With Increased RET Activity
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Skin Cancer (Non-Melanoma), Thyroid Cancer, Unknown Primary
NCT ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
Treatment Sites (1)
14.
A Phase 1 Study of Palbociclib in Combination with Cisplatin or Carboplatin in Advanced Solid Malignancies
Cancer Type
Unknown Primary
NCT ID
NCT02897375
Protocol IDs
Winship3263-16
NCI-2016-01037
IRB00089583
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
15.
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients With Advanced Solid Malignancies and Lymphoma With an Expansion in Select Malignancies
Cancer Type
Unknown Primary
NCT ID
NCT02922764
Protocol IDs
RGX-104-001
NCI-2017-00226
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
16.
A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Cancer Type
Brain Cancer , Eye Cancer, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02323880
Protocol IDs
ADVL1414
NCI-2014-02410
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
17.
A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF LORLATINIB IN ADVANCED CANCER PATIENTS
Cancer Type
Lymphoma, Unknown Primary
NCT ID
NCT03726333
Protocol IDs
B7461009
NCI-2019-01060
HEPATIC IMPAIRMENT
lorlatinib HEPATIC IMPAIRMENT
Treatment Sites (3)
18.
A Phase 1 Study Using Simvastatin in Combination With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
Cancer Type
Unknown Primary
NCT ID
NCT02390843
Protocol IDs
IRB00078790
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
21.
NCORP Trial
A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
Cancer Type
Unknown Primary
NCT ID
NCT02658890
Protocol IDs
CA017-003
NCI-2016-00153
2015-004914-79
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
22.
A Phase 1b / 2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
Cancer Type
Breast Cancer, Kidney Cancer, Unknown Primary
NCT ID
NCT03875313
Protocol IDs
CX-839-011
NCI-2019-02256
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
23.
A Phase 1b / 2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies
Cancer Type
Breast Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT02554812
Protocol IDs
B9991004
NCI-2015-02263
2015-002552-27
JAVELIN MEDLEY
s16-02110
27.
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Anti-PD1 in Adults With Head and Neck Cancer
Cancer Type
Unknown Primary
NCT ID
NCT03937141
Protocol IDs
ADU-CL-20
NCI-2019-04759
Treatment Sites (1)
28.
A Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT04022343
Protocol IDs
Winship4643-19
NCI-2019-02253
IRB00110583
Treatment Sites (2)
29.
A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
Cancer Type
Unknown Primary
NCT ID
NCT03742895
Protocol IDs
7339-002
NCI-2018-03519
2018-003007-19
MK-7339-002
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
30.
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
Cancer Type
Lung Cancer, Ovarian Cancer, Unknown Primary
NCT ID
NCT03836352
Protocol IDs
P1719-SUR-Z11
NCI-2019-03013
Keynote 903
Treatment Sites (2)
Emory Clinic
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
31.
NCORP Trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03706365
Protocol IDs
16598
NCI-2019-00897
I3Y-MC-JPCM
2016-004276-21
Treatment Sites (13)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
32.
33.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03395197
Protocol IDs
C3441021
NCI-2018-01651
TALAPRO-2
2017-003295-31
34.
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03833167
Protocol IDs
3475-630
NCI-2019-01629
MK-3475-630
2018-001974-76
KEYNOTE-630
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
36.
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
Cancer Type
Melanoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03635983
Protocol IDs
CA045-001
NCI-2018-02224
17-214-08
2018-001423-40
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
37.
A Phase I / 2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Cancer Type
Bladder Cancer, Cervical Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT01968109
Protocol IDs
CA224-020
NCI-2014-00315
2014-002605-38
38.
A Phase I / II Study of Concurrent Cetuximab and Nivolumab in Patients with Recurrent and / or Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Oral Cancer, Unknown Primary
NCT ID
NCT03370276
Protocol IDs
MCC-19178
NCI-2017-02373
Treatment Sites (1)
39.
A Phase I / II Study of Trifluridine / Tipiracil (TAS102) in Combination with Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers
Cancer Type
Pancreatic Cancer, Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03368963
Protocol IDs
Winship4146-17
NCI-2017-01661
IRB00098958
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
40.
A Phase I / II Trial of the PD-L1 Inhibitor, Durvalumab (MEDI4736) plus CV301 in Combination with Maintenance Chemotherapy for Patients with Metastatic Colorectal or Pancreatic Adenocarcinoma
Cancer Type
Pancreatic Cancer, Unknown Primary
NCT ID
NCT03376659
Protocol IDs
2017-1189
NCI-2017-02486
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
41.
A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab + / - Lenalidomide
Cancer Type
Neuroblastoma, Unknown Primary
NCT ID
NCT02573896
Protocol IDs
NANT 2013-01
NCI-2019-00106
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
43.
NCORP Trial
A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT03691493
Protocol IDs
Winship4472-18
NCI-2018-02000
IRB00105944
Treatment Sites (17)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
44.
A Phase II Study of Niraparib in Combination with EGFR Inhibitor Panitumumab in Patients with Advanced Colorectal Cancer
Cancer Type
Unknown Primary
NCT ID
NCT03983993
Protocol IDs
Winship4517-18
NCI-2018-02757
IRB00107377
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
45.
A Phase II Study of Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors
Cancer Type
Unknown Primary
NCT ID
NCT02574728
Protocol IDs
AFLACST1502
NCI-2015-01637
IRB00082488
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
46.
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients with RM SCCHN Who Have Failed Platinum Based Therapy
Cancer Type
Head and Neck Cancer, Oral Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03468218
Protocol IDs
Winship4234-17
NCI-2017-02419
IRB00100269
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
48.
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT03739710
Protocol IDs
205801
NCI-2018-03390
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
49.
A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT03091660
Protocol IDs
S1602
S1602
NCI-2016-00451
S1602
Treatment Sites (1)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
50.
A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
Cancer Type
Unknown Primary
NCT ID
NCT03550391
Protocol IDs
CCTG CE.7
CCTG CE.7
NCI-2018-00395
CE.7
Treatment Sites (2)
51.
A Pilot Study of Atezolizumab (MPDL3280A) following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Cancer Type
Unknown Primary
NCT ID
NCT02862275
Protocol IDs
10014
10014
NCI-2016-01232
PJC-023
Treatment Sites (3)
55.
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas
Cancer Type
Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03038672
Protocol IDs
10089
10089
NCI-2017-00120
MC168D
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
56.
58.
NCORP Trial
A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Cancer Type
Melanoma, Unknown Primary
NCT ID
NCT02224781
Protocol IDs
EA6134
NCI-2014-01747
Treatment Sites (16)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
60.
NCORP Trial
A Randomized, Double-Blind, Phase III Trial of Paclitaxel / Trastuzumab / Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT03199885
Protocol IDs
NRG-BR004
NRG-BR004
NCI-2017-01119
Treatment Sites (13)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
61.
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03767244
Protocol IDs
CR108535
NCI-2019-04921
2018-001746-34
56021927PCR3011
2018-001746-34
Treatment Sites (2)
62.
A Randomized, Phase II Study of Ficlatuzumab with or without Cetuximab in Patients with Cetuximab-Resistant, Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Oral Cancer, Unknown Primary
NCT ID
NCT03422536
Protocol IDs
1710965268
NCI-2017-02209
AVEO
AV-299-17-117i
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
63.
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas
Cancer Type
Colon/Rectal Cancer, Head and Neck Cancer, Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03783936
Protocol IDs
HCRN GI17-319
NCI-2018-03813
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
64.
A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults With Severe Sickle Cell Disease (BMT CTN #1503)
Cancer Type
Unknown Primary
NCT ID
NCT02766465
Protocol IDs
BMTCTN1503
NCI-2016-01386
1U01HL128568-01
Treatment Sites (3)
66.
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 in Patients With Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma
Cancer Type
Colon/Rectal Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03809624
Protocol IDs
Ph 1 INBRX-105
NCI-2019-02844
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
68.
ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study
Cancer Type
Unknown Primary
NCT ID
NCT02135419
Protocol IDs
AMC-A01
NCI-2014-00636
Treatment Sites (1)
69.
Biomolecular Effects of Topical Curcumin in HSIL Cervical Neoplasia
Cancer Type
Unknown Primary
NCT ID
NCT02944578
Protocol IDs
EU2971-15
NCI-2016-01405
IRB00079183
70.
Cabazitaxel with Abiraterone versus Abiraterone Alone Randomized Trial for Extensive Disease following Docetaxel: The CHAARTED2 Trial
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03419234
Protocol IDs
EA8153
EA8153
NCI-2017-00389
Treatment Sites (2)
71.
Combination of MEK Inhibitor Binimetinib and CDK4 / 6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
Cancer Type
Unknown Primary
NCT ID
NCT03981614
Protocol IDs
ACCRU-GI-1618
NCI-2019-03480
Treatment Sites (2)
72.
Communication App to Manage Symptoms and Improve Adjuvant Endocrine Therapy Adherence for Women With Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT03592771
Protocol IDs
17-05479-XP R073237380
NCI-2019-05690
1R01CA218155
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
73.
NCORP Trial
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Cancer Type
Appendix Cancer, Bone and Soft Tissue (including Sarcoma), Brain Cancer , Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT02834013
Protocol IDs
S1609
NCI-2016-01041
Treatment Sites (10)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Piedmont Fayette Hospital
Fayetteville
404-851-2340
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
75.
Dose Escalation Trial of Fractionated Stereotactic Radiosurgery for Brain Metastasis Greater Than 3cm
Cancer Type
Unknown Primary
NCT ID
NCT01705548
Protocol IDs
RAD2156-11
NCI-2012-01933
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
76.
NCORP Trial NCI Priority
EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type
Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCT ID
NCT02465060
Protocol IDs
EAY131
NCI-2015-00054
EAY131-A
EAY131-B
EAY131-E
EAY131-F
EAY131-G
EAY131-H
EAY131-Q
EAY131-R
EAY131-U
EAY131-V
Treatment Sites (29)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
The Medical Center of Central Georgia
Macon
Oncology Research Nurse
4786331738
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
77.
NCORP Trial
EROS: Engendering Reproductive Health within Oncologic Survivorship
Cancer Type
Unknown Primary
NCT ID
NCT01806129
Protocol IDs
E1Q11
NCI-2012-02869
ECOG-E1Q11
Treatment Sites (3)
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
79.
Increasing Socioeconomically Disadvantaged Patients' Engagement in Breast Cancer Surgery Decision Making through a Shared Decision Making Intervention
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT03766009
Protocol IDs
A231701CD
A231701CD
A231701CD
NCI-2018-00643
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
80.
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy
Cancer Type
Unknown Primary
NCT ID
NCT02445222
Protocol IDs
CCTL019A2205B
NCI-2015-01238
2014-001673-14
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
81.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
Cancer Type
Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary
NCT ID
NCT03698994
Protocol IDs
APEC1621J
APEC1621J
NCI-2018-02150
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
82.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1 / 2 / 3 / 4 Alterations
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCT ID
NCT03210714
Protocol IDs
APEC1621B
APEC1621B
NCI-2017-01159
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
83.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCT ID
NCT03213704
Protocol IDs
APEC1621A
APEC1621A
NCI-2017-01264
APEC1621A
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
84.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary
NCT ID
NCT03526250
Protocol IDs
APEC1621I
APEC1621I
NCI-2018-00863
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
85.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
Cancer Type
Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03213691
Protocol IDs
APEC1621E
APEC1621E
NCI-2017-01250
APEC1621E
Treatment Sites (1)
86.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCT ID
NCT03233204
Protocol IDs
APEC1621H
APEC1621H
NCI-2017-00766
APEC1621H
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
87.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
Cancer Type
Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03213652
Protocol IDs
APEC1621F
APEC1621F
NCI-2017-01243
APEC1621F
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
88.
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of Ly3023414 in Patients with Solid Tumors
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary
NCT ID
NCT03213678
Protocol IDs
APEC1621D
APEC1621D
NCI-2017-01249
APEC1621D
Treatment Sites (1)
89.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCT ID
NCT03155620
Protocol IDs
APEC1621SC
APEC1621SC
NCI-2017-01251
APEC1621SC
Treatment Sites (1)
90.
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Selected Solid Tumors
Cancer Type
Lung Cancer, Pancreatic Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03485209
Protocol IDs
SGNTV-001
NCI-2018-00676
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
91.
Percutaneous Image Guided Cryoablation of the Intercostobrachial Nerve for Management of Post Mastectomy Pain Syndrome
Cancer Type
Unknown Primary
NCT ID
NCT03293940
Protocol IDs
RAD4068-17
NCI-2017-01824
IRB00094527
Treatment Sites (4)
92.
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
Cancer Type
Unknown Primary
NCT ID
NCT02717507
Protocol IDs
ALTE1621
NCI-2016-00232
COG-ALTE1621
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
93.
Phase 1 / 2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
Cancer Type
Breast Cancer, Cervical Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCT ID
NCT03674567
Protocol IDs
FLX475-02
NCI-2019-00102
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
95.
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Cancer Type
Cervical Cancer, Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT02503423
Protocol IDs
ASTX660-01
NCI-2017-01760
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
96.
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Cancer Type
Ewing Sarcoma, Kidney Cancer, Unknown Primary
NCT ID
NCT02867592
Protocol IDs
ADVL1622
NCI-2016-01258
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
97.
Phase I / II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy
Cancer Type
Kidney Cancer, Lung Cancer, Melanoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03656718
Protocol IDs
CA209-8KX
NCI-2018-02324
2018-001585-42
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
98.
Phase I Integrated Biomarker Trial of VX15 / 2503 in Combination with Ipilimumab or Nivolumab in Patients with Pancreatic and Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Pancreatic Cancer, Unknown Primary
NCT ID
NCT03373188
Protocol IDs
Winship4142-17
NCI-2017-01618
IRB00098707
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
99.
Phase I Study of MEK 162 for Children with Progressive or Recurrent Cancer and a Phase II Study for Children with Low-Grade Gliomas and Other Ras / Raf / MAP Pathway Activated Tumors
Cancer Type
Brain Cancer , Unknown Primary
NCT ID
NCT02285439
Protocol IDs
ChildrensHLA
NCI-2014-02168
s17-00228
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
100.
Phase II Multi-Institutional Study of Low-Dose (2Gy x 2) Palliative Radiotherapy in the Treatment of Symptomatic Bone Metastases from Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma, Unknown Primary
NCT ID
NCT03858205
Protocol IDs
16M-18-2
NCI-2018-03600
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
101.
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1 / PD-L1 Based Immunotherapy
Cancer Type
Unknown Primary
NCT ID
NCT03547973
Protocol IDs
IMMU-132-06 - TROPHY U-01
NCI-2018-03421
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
102.
Phase II Randomized Study of Two Home-Based Interventions for Sleep-Wake Disturbances in Cancer Survivors
Cancer Type
Unknown Primary
NCT ID
NCT00993928
Protocol IDs
NCCTG N07C4
103.
Phase II Trial of Nivolumab and Metformin in Patients with Treatment Refractory MSS Metastatic Colorectal Cancer
Cancer Type
Unknown Primary
NCT ID
NCT03800602
Protocol IDs
Winship4494-18
NCI-2018-02201
IRB00106678
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
104.
NCORP Trial
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT03418961
Protocol IDs
S1501
S1501
SWOG-S1501
NCI-2016-01047
Treatment Sites (17)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
105.
Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
Cancer Type
Brain Cancer , Unknown Primary
NCT ID
NCT01117168
Protocol IDs
ACCRN07
NCI-2009-00331
CDR0000069496
10-C-0111
107.
Rad3179-16 (MK-3475-423) Pilot Study of Pembrolizumab and Stereotactic Radio-Surgery (SRS) for Patients with Melanoma or Non-small Cell Lung Cancer (NSCLC) Brain Metastases (BM)
Cancer Type
Eye Cancer, Lung Cancer, Melanoma, Unknown Primary
NCT ID
NCT02858869
Protocol IDs
RAD3179-16
NCI-2016-00718
IRB00086461
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
108.
Randomized Trial of Epsilon Aminocaproic Acid Versus Platelet Transfusions for the Prevention of Bleeding in Thrombocytopenic Patients With Hematological Malignancies.
Cancer Type
Unknown Primary
NCT ID
NCT02074436
Protocol IDs
IRB00066504
WINSHIP2429-13
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
110.
Resistance Training to Improve Fatigue and Physical Function in Postmenopausal Breast Cancer Survivors
Cancer Type
Unknown Primary
NCT ID
NCT03539835
Protocol IDs
EU4372-18
NCI-2018-01742
IRB00103558
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
111.
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Cancer Type
Lymphoma, Multiple Myeloma, Unknown Primary
NCT ID
NCT02693535
Protocol IDs
Pro00014171
NCI-2017-00510
Treatment Sites (2)
112.
NCORP Trial
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Cancer Type
Eye Cancer, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02402244
Protocol IDs
APEC14B1
NCI-2014-02057
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
The Medical Center of Central Georgia
Macon
Oncology Research Nurse
4786331738
113.
Weight Loss in Patients with Advanced Stage Pancreatic Cancer: Role of Serotonin and Effects of Telotristat Ethyl
Cancer Type
Pancreatic Cancer, Unknown Primary
NCT ID
NCT03910387
Protocol IDs
Winship4441-18
NCI-2018-01977
IRB00105292
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.